Latest Novakand Pharma News & Updates

See the latest news and media coverage for Novakand Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Novakand Pharma

Biopharmaceutical developer of biomarker-guided orphan drugs

novakand.com

Company type: Public company
Number of employees: 4–10
Industry: Pharmaceuticals

Last updated October 12

Latest news about Novakand Pharma

In short: Novakand Pharma was delisted, pivoted to cancer drugs, and appointed Berit Lindholm acting CEO.

Company announcements

October 12 Novakand Pharma

Novakand Pharma appoints Berit Lindholm as acting CEO

Lindholm will take up the position on November 4 after Thomas Olin. The board plans to raise capital to finance a clinical phase 2 study of rugocrixan in 2028.

August 28 Novakand Pharma

Novakand Pharma presents the half-year report for the first half of 2026

The company reports about Nasdaq delisting, new board and strategic shift towards cancer drugs at an operating loss of 6.3 million kronor.

July 16 Novakand Pharma

Novakand Pharma announces regarding management, website and extraordinary general meeting

Thomas Olin becomes acting CEO, Björn Petersson CFO, new website launched, and extraordinary general meeting in September with items about capital raising.

June 25 Novakand Pharma

Novakand Pharma shifts strategy to orphan drugs for cancer

Focus shifts from cardiovascular diseases to treatment-resistant ovarian cancer and leukemia, with support from new board and clinical data.

Media coverage

June 23 Barron's

Novakand Pharma AB

Novakand Pharma AB engages in the research, development, and sale of drug candidates to pharmaceutical companies. It focuses on Fractalkine program which develops a candidate...

March 3 Malmö Film & TV

MFN.se > Novakand Pharma > Novakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting

Background Novakand Pharma AB (”Novakand” or the ”Company”) announced on February 24, 2026, that Nasdaq had rejected Novakand's application for continued listing on First North...

February 24 Kauppalehti

KDventures’s portfolio company SVF Vaccines announces that the intended merger with Novakand will not be carried out following negative decision from Nasdaq

STOCKHOLM, Sweden, February 24, 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma...

February 24 Finanznachrichten

The observation status for Novakand Pharma AB is updated

On November 25, 2025, the shares in Novakand Pharma AB (the "Company") were given observation status with reference to the Company's disclosure of its interim...

Never miss news about Novakand Pharma

Track Novakand Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Novakand Pharma competitors & trending companies

Browse news for competitors to Novakand Pharma and other trending companies.